Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies (Q34620205)

3 August 2017

1 reference

title

Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies (English)

1 reference

3 August 2017

Olaf H Temmink

1

1 reference

3 August 2017

Tomohiro Emura

2

1 reference

3 August 2017

Michiel de Bruin

3

1 reference

3 August 2017

Masakazu Fukushima

4

1 reference

3 August 2017

Godefridus J Peters

5

1 reference

3 August 2017

language of work or name

1 reference

18 April 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

98

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

779-789

1 reference

SYNTHESES OF 5-TRIFLUOROMETHYLURACIL AND 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Antiviral drugs in current clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Thymidylate synthase: a target for combination therapy and determinant of chemotherapeutic response in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)-2'-deoxyuridine 5'-monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2'-deoxyuridylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: discovery of novel orally active inhibitors of human thymidine phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 2: optimization of inhibitors of human thymidine phosphorylase and their selectivity with uridine phosphorylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Angiogenesis and its role in colorectal tumor and metastasis formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Thymidine phosphorylase is angiogenic and promotes tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Angiogenic activity of enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

The activity and expression of thymidine phosphorylase in human solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

The role of thymidine phosphorylase and uridine phosphorylase in (fluoro)pyrimidine metabolism in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Quantitative 19F NMR study of trifluorothymidine metabolism in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Structural analyses reveal two distinct families of nucleoside phosphorylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

High interstitial fluid pressure - an obstacle in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00477.X

10.1111/J.1349-7006.2007.00477.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference